S19 Ep5: Navigating Patient-Centric Treatment Administration Strategies in Myeloma

In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed how on-body subcutaneous administration methods are affecting multiple myeloma management and how these administrations could be a key focus of future health care initiatives. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.

In the second episode of a 3-part series, Drs Faiman and Ailawadhi explained how on-body administration of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection is setting the stage for future patient-centric treatment methods, and the pair discussed experiences with this method.

In the first episode, Drs Faiman and Ailawadhi detailed the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management.